Omly assigned patients among treated and untreatedSieuwerts et al. Breast Cancer Research 2010, 12:R103 http://breast-cancer-research.com/content/12/6/RPage 8 ofFigure 1 Metastasis-free survival as a function of dichotomized DC-SCRIPT. Metastasis-free survival is shown as a function of dichotomized DC-SCRIPT in 837 lymph-node negative, primary breast cancer patients after subdividing them accordin
F 1.9 . The homeostasis model assessment for insulin resistance (HOMA-IR) was used to estimate insulin resistance as determined by the following formula: ((fasting insulin (U/mL) ?fasting glucose (mmol/liter))/22.5 [24]. Serum estradiol was measured using an electrochemiluminescence immunoassay analyzer (Roche Modular Analytics E170; Roche, Mannheim, Germany) with a CV of 2.4 . Serum adiponectin l
F 1.9 . The homeostasis model assessment for insulin resistance (HOMA-IR) was used to estimate insulin resistance as determined by the following formula: ((fasting insulin (U/mL) ?fasting glucose (mmol/liter))/22.5 [24]. Serum estradiol was measured using an electrochemiluminescence immunoassay analyzer (Roche Modular Analytics E170; Roche, Mannheim, Germany) with a CV of 2.4 . Serum adiponectin l
Ategories. Patients having ER-negative and PR-negative was designated as the ER/PR-negative group, and ER-positive or PR-positive as the ER/PR-positive group. Because significant interactions were observed between ER/PR status and the primary measures, and because the use of adjuvant endocrine therapy and prognosis varies according to ER/PR receptor status, we analyzed data according to ER/PR-posi
Omly assigned patients among treated and untreatedSieuwerts et al. Breast Cancer Research 2010, 12:R103 http://breast-cancer-research.com/content/12/6/RPage 8 ofFigure 1 Metastasis-free survival as a function of dichotomized DC-SCRIPT. Metastasis-free survival is shown as a function of dichotomized DC-SCRIPT in 837 lymph-node negative, primary breast cancer patients after subdividing them accordin